75 related articles for article (PubMed ID: 36808895)
1. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
[TBL] [Abstract][Full Text] [Related]
2. BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract][Full Text] [Related]
3. MesoGraph: Automatic profiling of mesothelioma subtypes from histological images.
Eastwood M; Sailem H; Marc ST; Gao X; Offman J; Karteris E; Fernandez AM; Jonigk D; Cookson W; Moffatt M; Popat S; Minhas F; Robertus JL
Cell Rep Med; 2023 Oct; 4(10):101226. PubMed ID: 37816348
[TBL] [Abstract][Full Text] [Related]
4. Overexpression or absence of calretinin in mouse primary mesothelial cells inversely affects proliferation and cell migration.
Blum W; Pecze L; Felley-Bosco E; Schwaller B
Respir Res; 2015 Dec; 16():153. PubMed ID: 26695618
[TBL] [Abstract][Full Text] [Related]
5. Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data.
Eastwood M; Marc ST; Gao X; Sailem H; Offman J; Karteris E; Fernandez AM; Jonigk D; Cookson W; Moffatt M; Popat S; Minhas F; Robertus JL
Artif Intell Med; 2023 Sep; 143():102628. PubMed ID: 37673586
[TBL] [Abstract][Full Text] [Related]
6. Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma.
Churg A; Naso JR
Am J Surg Pathol; 2024 May; 48(5):632. PubMed ID: 38223954
[No Abstract] [Full Text] [Related]
7. Peritoneal Malignant Mesothelioma Metastasizing to Lymph Node in Young Male-a Case Report.
Singh A; Bansal C; Singla D; More S; Chabhra S; Bashir S
Indian J Surg Oncol; 2024 Mar; 15(1):145-148. PubMed ID: 38511037
[TBL] [Abstract][Full Text] [Related]
8. Case report: Abdominal mesothelioma in
Troncoso I; Brown J; Isla C; Lajara JM; Ebner M; Fehrmann-Cartes K
Front Vet Sci; 2024; 11():1341815. PubMed ID: 38807940
[TBL] [Abstract][Full Text] [Related]
9. Overdiagnosis of diffuse mesothelioma: A reminder that pathologists need to think outside the "immunohistochemistry diagnostic box".
Marchevsky AM
Ann Diagn Pathol; 2024 Feb; 68():152264. PubMed ID: 38281847
[No Abstract] [Full Text] [Related]
10. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
Rossi G; Righi L; Barbisan F; Tiseo M; Spagnolo P; Grosso F; Pisapia P; Malapelle U; Sculco M; Dianzani I; Abate-Daga L; Davolio MC; Ceresoli GL; Galetta D; Pasello G; Novello S; Bironzo P
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673021
[TBL] [Abstract][Full Text] [Related]
11. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
12. Diffuse intrapulmonary mesothelioma mimicking pulmonary lepidic adenocarcinoma: a rare case report and review of the literature.
RanYue W; ChunYan W; Likun H; LiPing Z; JieLu L; ZhengWei D
Diagn Pathol; 2023 May; 18(1):64. PubMed ID: 37194050
[TBL] [Abstract][Full Text] [Related]
13. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
14. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
[TBL] [Abstract][Full Text] [Related]
15. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
